| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
57,860,000 |
| Market
Cap: |
227.39(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.47 - $11.89 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 14.8 |
| Insider 6 Months : 14.8 |
| Insider 3/6 Months : 29.9 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aldeyra Therapeutics is a biotechnology company focused on discovering and developing therapies designed to treat immune-mediated diseases. Co.'s primary product candidate, reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. Co. has additional product candidates in development for autoimmune diseases and other immune-mediated disease, as well as for proliferative vitreoretinopathy (PVR) and other retinal diseases. Co. has rights to ADX-2191, a vitreous-compatible methotrexate formulation for intraocular injection, for the prevention of PVR, a retinal disease, and primary vitreoretinal lymphoma, a rare cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
682,265 |
682,265 |
682,265 |
2,150,494 |
| Total Buy Value |
$2,768,372 |
$2,768,372 |
$2,768,372 |
$11,311,413 |
| Total People Bought |
1 |
1 |
1 |
3 |
| Total Buy Transactions |
5 |
5 |
5 |
17 |
| Total Shares Sold |
250,945 |
250,945 |
3,007,444 |
3,007,444 |
| Total Sell Value |
$805,803 |
$805,803 |
$5,259,111 |
$5,259,111 |
| Total People Sold |
3 |
3 |
4 |
4 |
| Total Sell Transactions |
7 |
7 |
9 |
9 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Edelman Joseph |
10% Owner |
– – • |
2022-08-03 |
4 |
B |
$5.84 |
$584,000 |
I/I |
100,000 |
10,901,985 |
1.5 |
7% |
|
| Edelman Joseph |
10% Owner |
– – • |
2022-08-02 |
4 |
B |
$5.59 |
$2,305,350 |
I/I |
412,406 |
10,801,985 |
1.5 |
12% |
|
| Edelman Joseph |
10% Owner |
– – • |
2022-08-01 |
4 |
B |
$5.05 |
$728,134 |
I/I |
144,185 |
10,389,579 |
1.5 |
22% |
|
| Edelman Joseph |
10% Owner |
– – • |
2022-07-29 |
4 |
B |
$5.03 |
$1,117,279 |
I/I |
222,123 |
10,245,394 |
1.5 |
22% |
|
| Edelman Joseph |
10% Owner |
– – • |
2022-07-28 |
4 |
B |
$5.00 |
$596,960 |
I/I |
119,392 |
10,023,271 |
1.5 |
22% |
|
| Machatha Stephen |
Chief Development Officer |
• – – |
2022-07-15 |
4 |
A |
$0.00 |
$0 |
D/D |
185,605 |
273,263 |
|
- |
|
| Greenberg Bruce |
See Remarks |
• – – |
2022-07-15 |
4 |
A |
$0.00 |
$0 |
D/D |
126,087 |
133,900 |
|
- |
|
| Joyce Martin Joseph |
Director |
– • – |
2022-06-23 |
4 |
B |
$3.48 |
$15,025 |
D/D |
4,323 |
23,967 |
2.39 |
51% |
|
| Brady Todd C |
President and CEO |
• • – |
2022-06-23 |
4 |
B |
$3.36 |
$59,546 |
D/D |
17,700 |
1,216,535 |
2.81 |
51% |
|
| Greenberg Bruce |
See RemarksOfficer |
• – – |
2022-05-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
7,813 |
|
133% |
|
| Machatha Stephen |
Chief Development Officer |
• – – |
2022-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
64,395 |
87,658 |
|
- |
|
| Brady Todd C |
President and CEO |
• • – |
2022-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
250,000 |
1,198,835 |
|
- |
|
| Reed Joshua |
Chief Financial Officer |
• – – |
2022-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
93,322 |
274,825 |
|
- |
|
| Edelman Joseph |
10% Owner |
– – • |
2021-05-03 |
4 |
B |
$12.50 |
$15,000,000 |
I/I |
1,200,000 |
9,903,879 |
1.5 |
-30% |
|
| Brady Todd C |
President and CEO |
• • – |
2021-04-12 |
4 |
A |
$0.00 |
$0 |
D/D |
46,619 |
948,835 |
|
- |
|
| Edelman Joseph |
10% Owner |
– – • |
2021-01-19 |
4 |
B |
$9.50 |
$13,000,000 |
I/I |
1,368,421 |
8,703,879 |
1.5 |
-5% |
|
| Edelman Joseph |
10% Owner |
– – • |
2021-01-08 |
4 |
B |
$7.60 |
$5,137,668 |
I/I |
550,000 |
7,335,458 |
1.5 |
13% |
|
| Edelman Joseph |
10% Owner |
– – • |
2021-01-07 |
4 |
B |
$8.13 |
$4,065,000 |
I/I |
500,000 |
6,785,458 |
1.5 |
42% |
|
| Machatha Stephen |
Chief Development OfficerOffic |
• – – |
2020-12-08 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
211 |
|
52% |
|
| Machatha Stephen |
Chief Development OfficerOffic |
• – – |
2020-12-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
20,091 |
|
52% |
|
| Douglas Richard |
Director |
– • – |
2020-03-16 |
4 |
B |
$2.75 |
$110,000 |
D/D |
40,000 |
125,000 |
2.39 |
331% |
|
| Reed Joshua |
Chief Financial Officer |
• – – |
2020-03-02 |
4/A |
A |
$0.00 |
$0 |
D/D |
137,707 |
173,481 |
|
- |
|
| Mcmullin David |
Chief Commercial Officer |
• – – |
2020-03-02 |
4/A |
A |
$0.00 |
$0 |
D/D |
247,480 |
255,183 |
|
- |
|
| Reed Joshua |
Chief Financial Officer |
• – – |
2020-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
250,000 |
285,774 |
|
- |
|
| Mcmullin David |
Chief Commercial Officer |
• – – |
2020-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
250,000 |
257,703 |
|
- |
|
112 Records found
|
|
Page 2 of 5 |
|
|
0.01 (0.25%) 
